Nyxoah (NASDAQ:NYXH) and Mitesco (OTCMKTS:MITI) Critical Analysis

Nyxoah (NASDAQ:NYXH) and Mitesco (OTCMKTS:MITI) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

0.0% of Mitesco shares are held by institutional investors. 17.1% of Nyxoah shares are held by insiders. Comparatively, 4.9% of Mitesco shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Nyxoah and Mitesco, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nyxoah	0	0	4	0	3.00
Mitesco	0	0	0	0	0.00

Nyxoah currently has a consensus target price of $14.50, indicating a potential upside of 88.80%. Given Nyxoah’s stronger consensus rating and higher probable upside, research analysts clearly believe Nyxoah is more favorable than Mitesco.

Earnings & Valuation

This table compares Nyxoah and Mitesco”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nyxoah	$4.89 million	53.49	-$64.10 million	($2.13)	-3.61
Mitesco	$40,000.00	110.09	-$2.51 million	N/A	N/A

Mitesco has lower revenue, but higher earnings than Nyxoah.

Profitability

This table compares Nyxoah and Mitesco’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nyxoah	-1,571.39%	-63.37%	-46.67%
Mitesco	1,456.66%	N/A	-1,202.21%

Volatility and Risk

Nyxoah has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, Mitesco has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

About Mitesco

Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.